An Open-Label, Parallel Group, Single And Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function.

Trial Profile

An Open-Label, Parallel Group, Single And Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function.

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Nov 2010

At a glance

  • Drugs Maraviroc (Primary) ; Ritonavir; Saquinavir
  • Indications HIV infections; HIV-1 infections
  • Focus Pharmacokinetics
  • Sponsors Pfizer; ViiV Healthcare
  • Most Recent Events

    • 18 Nov 2010 Additional lead trial centre 'ViiV Healthcare' identified as reported by ClinicalTrials.gov.
    • 13 Jan 2010 Actual patient number (30) added as reported by ClinicalTrials.gov.
    • 25 Dec 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top